Agree with the timelines you’ve laid out. And yes, I remember during the call Rohan and the team had to take stock and refocus on what PYC can execute in the near term; it’ll be a monogenic view for now.
Here’s a theory… In a recent announcement they shifted their wording to introduce the co-lead terminology; in the past Sahm referred to VP-002 coming in 6 months behind - known fact that VP-001 is delayed; but does this automatically push out VP-002 timelines also? are assets being developed independently - with assets being worked up in parallel fashion or are asset timelines sequentially connected/dependent?
Had hoped PYC (maybe still am) was going to pull a rabbit out of the hat and say VP-001 and VP-002 are ready to enter IND together; that they’ve been working up VP-002 in stealth and the design of the IND was shaped in such a way that allowed for separate validation of the delivery platform - resulting in PYC-001 being 50% validated as the FDA/industry is amazed with with the safety and efficacy readouts of VP-001/2 and wonder why the industry doesn’t pivot to follow PYC, common disease indications included (hence PYC-001 and any big ocular targets that they are keeping undisclosed) Am I being a tad bit optimistic again?
As an aside, the 3 articles you shared are amazing at explaining the malaise in sentiment affecting the market (and PYC’s share price); you’ve already been warning us of the danger/data surfacing to date of having AAV (viral vectors - refer to bottom row of the below table to compare against CPP; is PYC’s platform) as the default/inertia choice of PYC competitors/ general biotech industry. some of the harm to patients is very sad to read, and would have scared investors.
PYC had been trying to warn/or encourage people to listen/join their camp regarding the dangers of choosing the default delivery mechanism through scientific posters.. maybe now they’ll listen that not all delivery platforms are built equally, and that harm could have been avoided; at least the FDA seem to have concurred enough to support our approach (early days I know). Our non-GLP tox data hopefully paints the picture, but hopefully our GLP later this year will reinforce the message:
PYC Price at posting:
9.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)